Smn was chosen as a control, because, like GlyRS, it is expressed both in the nucleus and cytoplasm (33), it has been identified in axonal projections (10,34), and its dysfunction is associated with a disorder that affects the lower motor neurons (spinal muscular atrophy) (34,35). The gene discussed is GARS1; the disease is spinal muscular atrophy.